nintedanibpirfenidonegastro-oesophageal reflux diseasecardiovascular diseaseDiabetesmajor depressive illnessidiopathic pulmonary fibrosislung cancerantifibrotics
…baseline (pirfenidone FVC 50%–80% males 54.7% vs females 47.6%, nintedanib FVC 50%–80% males 47.0% vs females 41.5%, p<0.001), a larger pr…